Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer

Back

Gilbert Glady

Gilbert Glady

European Bio Immune(G)ene Medicine Association ,France

Title: BI(G)MED -Bio Immune(G)ene Medicine as an innovative nanotherapeutical immunotherapy of chronic viral reactivations related to EBV

Biography

Biography: Gilbert Glady

Abstract

The term "viral reactivation" is far from being widely accepted by the scientific community; perhaps this is due to an initial semantic misunderstanding of the notions of infection and reactivation, the second not being a particular form of the first, but something very different coming under a permanent but somehow restrained conflict existing between a latent and recurrent virus and the immune system. EBV is among all viruses the one where the concept of reactivation applies the best, with its genome being of consistent size and very adaptive, able to modulate various types of latency, to mimic the immune reactions engaged against him, to integrate into cellular DNA to controll it and ultimately immortalize the carrying cell. This viral reactivation, expression of a conflict whose outcome will long remain uncertain, will be able to generate a large number of pathological disorders, ranging from a banal chronic fatigue syndrome to malignancies, to a large number of auto-immune diseases. Once the biological diagnosis has been made, it is important to implement a treatment capable of neutralizing the aggressor and preventing him from initiating the pathophysiological processes responsible for the mentioned above disorders. This possibility exists today by resorting to a therapy using ultra low doses of various types of immunocompetent molecules, but also of epigenetic regulators such as non-coding RNAs being of viral origin or belonging to the host cell. Some clinical examples will make it possible to better specify the therapeutic procedure used and to emphasize its biological effectiveness.